MOG antibody non-P42 epitope is associated with a higher risk of relapse in paediatric MOGAD.

IF 8.7 1区医学 Q1 CLINICAL NEUROLOGY

Journal of Neurology, Neurosurgery, and Psychiatry Pub Date : 2025-03-28 DOI:10.1136/jnnp-2024-335579

Aseel El Hajj, Anne Ruiz, Antoine Gavoille, Justine Couturier, Pascale Giraudon, Lakhdar Benyahya, Lisa Malaise, Maxime Bigotte, Claire Benetollo, Gaetan Amorim, Julia Roux, Carole Leroy, Ann-Kathrin Kogel, Ilya Ayzenberg, Friedemann Paul, Sudarshini Ramanathan, Russell C Dale, Kumaran Deiva, Fabienne Brilot, Romain Marignier

{"title":"MOG antibody non-P42 epitope is associated with a higher risk of relapse in paediatric MOGAD.","authors":"Aseel El Hajj, Anne Ruiz, Antoine Gavoille, Justine Couturier, Pascale Giraudon, Lakhdar Benyahya, Lisa Malaise, Maxime Bigotte, Claire Benetollo, Gaetan Amorim, Julia Roux, Carole Leroy, Ann-Kathrin Kogel, Ilya Ayzenberg, Friedemann Paul, Sudarshini Ramanathan, Russell C Dale, Kumaran Deiva, Fabienne Brilot, Romain Marignier","doi":"10.1136/jnnp-2024-335579","DOIUrl":null,"url":null,"abstract":"Background: Biomarkers for predicting myelin oligodendrocyte glycoprotein antibody (Ab)-associated disease (MOGAD) clinical course are still missing. Binding capacity to a mutant MOG protein variant (MOG-P42S; non-P42) was shown to correlate with an increased relapse risk in adult patients.The objective of our study was to assess the frequency of binding to the non-P42 MOG variant in a cohort of paediatric MOGAD and to investigate its association with specific clinical profiles and disease course.Methods: We included children with MOG-Ab seropositive samples collected after their first demyelinating episode from five different centres. We performed live cell-based assays with native full-length MOG (MOG-FL) and mutant MOG-P42S and correlated the results with clinical data.Results: Of the 81 MOG-FL identified patients serum, 40 bound the non-P42 MOG. Non-P42 patients exhibited an earlier median age of onset (p=0.002). Phenotype distribution was different between groups (p=0.001), with non-P42 patients predominantly exhibiting acute disseminated encephalomyelitis phenotype. Notably, the non-P42 group was associated with a higher relapse rate (relative rate: 2.6 (95% CI 1.1 to 6.2), p=0.03), adjusted for clinical phenotype.Conclusion: Non-P42 is a promising biomarker for predicting relapse in paediatric MOGAD patients.","PeriodicalId":16418,"journal":{"name":"Journal of Neurology, Neurosurgery, and Psychiatry","volume":" ","pages":""},"PeriodicalIF":8.7000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology, Neurosurgery, and Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/jnnp-2024-335579","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Biomarkers for predicting myelin oligodendrocyte glycoprotein antibody (Ab)-associated disease (MOGAD) clinical course are still missing. Binding capacity to a mutant MOG protein variant (MOG-P42S; non-P42) was shown to correlate with an increased relapse risk in adult patients.The objective of our study was to assess the frequency of binding to the non-P42 MOG variant in a cohort of paediatric MOGAD and to investigate its association with specific clinical profiles and disease course.

Methods: We included children with MOG-Ab seropositive samples collected after their first demyelinating episode from five different centres. We performed live cell-based assays with native full-length MOG (MOG-FL) and mutant MOG-P42S and correlated the results with clinical data.

Results: Of the 81 MOG-FL identified patients serum, 40 bound the non-P42 MOG. Non-P42 patients exhibited an earlier median age of onset (p=0.002). Phenotype distribution was different between groups (p=0.001), with non-P42 patients predominantly exhibiting acute disseminated encephalomyelitis phenotype. Notably, the non-P42 group was associated with a higher relapse rate (relative rate: 2.6 (95% CI 1.1 to 6.2), p=0.03), adjusted for clinical phenotype.

Conclusion: Non-P42 is a promising biomarker for predicting relapse in paediatric MOGAD patients.

查看原文本刊更多论文

MOG抗体非p42表位与儿童MOGAD复发的高风险相关。

背景：预测髓鞘少突胶质细胞糖蛋白抗体（Ab）相关疾病（MOGAD）临床病程的生物标志物仍然缺失。MOG蛋白突变体（MOG- p42s）的结合能力；非p42)与成人患者复发风险增加相关。本研究的目的是评估儿童MOGAD队列中与非p42 MOG变体结合的频率，并调查其与特定临床特征和疾病病程的关系。方法：我们从五个不同的中心收集了MOG-Ab血清阳性样本，这些样本是在首次脱髓鞘发作后收集的。我们用天然全长MOG （MOG- fl）和突变MOG- p42s进行了活细胞检测，并将结果与临床数据相关联。结果：81例MOG- fl鉴定患者血清中，40例结合非p42 MOG。非p42患者表现出更早的中位发病年龄（p=0.002）。两组间表型分布不同（p=0.001），非p42患者主要表现为急性播散性脑脊髓炎表型。值得注意的是，经临床表型调整后，非p42组的复发率较高（相对复发率：2.6 (95% CI 1.1 - 6.2), p=0.03）。结论：Non-P42是预测小儿MOGAD患者复发的有希望的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neurology, Neurosurgery, and Psychiatry 医学-精神病学

CiteScore

15.70

自引率

1.80%

发文量

888

审稿时长

6 months

期刊介绍： The Journal of Neurology, Neurosurgery & Psychiatry (JNNP) aspires to publish groundbreaking and cutting-edge research worldwide. Covering the entire spectrum of neurological sciences, the journal focuses on common disorders like stroke, multiple sclerosis, Parkinson’s disease, epilepsy, peripheral neuropathy, subarachnoid haemorrhage, and neuropsychiatry, while also addressing complex challenges such as ALS. With early online publication, regular podcasts, and an extensive archive collection boasting the longest half-life in clinical neuroscience journals, JNNP aims to be a trailblazer in the field.